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CURRENT PROJECT

Purpose: The current survey aims to determine the various ways in which urologists at all levels of training view the nature
of their relationships with industry representatives, and the effects these relationships may have on clinical practice and
behavior.
Methods: We sent an anonymous SurveyMonkey® questionnaire to a cohort of approximately 1700 practicing urologists in
various urologic subspecialties across the country. The questionnaire elicited information related to demographics, personal
awareness of institutional guidelines regarding PR/DMR, and opinions regarding the following:
• the ability of industry-supplied gifts to compromise judgment
• the utility and appropriateness of industry representatives in the clinical setting
• the effects of governmental regulations addressing physician-industry contact
• the effects of receipt of promotional items in influencing clinical behaviors
• the need for laws governing physician contact with industry representatives
Opinions were reported on 5-point Likert scales ranging from “Strongly Agree” to “Strongly Disagree” allowing the
respondent the freedom to be “Undecided”. Finally, a free text response was made available at the end of the survey for
comments and feedback regarding the survey.
In the analysis phase “Strongly Agree” and “Agree” responses were pooled, as were “Strongly Disagree” and “Disagree”.
Four respondents were excluded from the final analysis because they failed to complete the opinions sections regarding
PR/DMR.
PR=Pharmaceutical Representatives
DMR=Device Manufacturer Representatives
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OPINIONS ON PR & DMR

A substantial body of research examines the nature of physician-industry relationships, with many authors concluding that
such intimate ties invite major conflicts of interest. The most comprehensive definition for conflict of interest can be found
in a 1993 NEJM article1: “A set of conditions in which professional judgment concerning a patient’s welfare…can be
influenced by financial gain. Paid speaking engagements, gifts, travel, owning of company shares etc.” Conflicts of interest
arise because physicians are the target of substantial product marketing. Doctors’ offices are inundated with drug samples,
pens, notepads, all for purpose of creating familiarity with a drug name or device brand. Doctors also receive lunch-hour
presentations billed as educational events aimed at teaching the group about new medications or the updated version of a
device being introduced to market.
Doctors feel that industry reps provide important teaching and training opportunities which would otherwise go
unfulfilled2. Indeed, reps can have such intimate roles in patient care that a study of surgeons found that these physicians
viewed their device reps as valuable members of the surgical team2. But research shows that despite doctors’ insistence
otherwise, sponsored CME demonstrably leads to increases in prescription rates of the promoted medication by the
attendant physicians3,4. In the surgical suite, it has been shown that in much the same way as regular interaction with PR
increases the chance of a drug being added to a hospital’s formulary5, regular contact with DMR increases the likelihood
that the devices they market will be used over a competitor’s, regardless of differences in efficacy or functionality. This
problem is further compounded by the brand loyalty that surgeons maintain for an extended time6. This has significant
effects on healthcare costs. One study found that up to 61% of a hospitals expenditure on surgical devices goes to
preference items7, an area where the presence of a device rep has a substantial impact.
Despite the amount of “education” physicians are receiving, research has also shown that having an established relationship
with pharmaceutical representatives actually reduces rather than increases physician awareness of adverse drug effects8.
A 2000 landmark article was published in JAMA reviewing 16 previous studies regarding these relationships, reporting
averages of 4 monthly interactions and the receipt of 6 gifts per year from industry representatives3, either pharmaceutical
representatives (PR), or device manufacturer representatives (DMR). Later studies showed even greater numbers of meetings
per month with industry representatives9. Indeed these interaction are pervasive, accepted as simply part of the healthcare
industry milieu, but the effects are undeniable, and greater awareness of them is paramount to ensuring equity in healthcare
delivery.

Disagree

RESULTS
Undecided

BACKGROUND

44%

43%

27%

13%

DMR perform an important
teaching function

85%

94%

92%

DMR provide useful
information about newly
introduced devices
DMR should be banned from
the OR

69%

44%

15%
Discussions with DMR have no
impact on my use of surgical
devices

92%

43%

19%

6%

Acceptance of promotional
items from DMR has no impact
on which surgical device I use

IMPORTANT HIGHLIGHTS
In our survey cohort, most respondents (80%) believed that physicians
could be compromised by gifts in excess of 50USD. 43% of respondents
had either an ill-defined idea or no awareness at all of the limits their
institution places on contact with pharmaceutical representatives, with a
comparable 51% lacking awareness of policies regarding device
manufacturer representatives. Most respondents viewed industry reps
as performing important educational functions. 73% believe that
acceptance of promotional items from pharmaceutical reps has no
impact on their personal prescribing behaviors, versus 15% of clinicians
who believe that receipt of promo items from reps does impact clinical
decisions. Respondents were split on that same measure regarding
promo items from device reps, with 44% perceiving an impact and 43%
perceiving no impact. Regarding free-text responses, comments
included suggestions for syntax and stylistic changes, as well as calls to
clarify various items on the questionnaire to better elucidate distinctions
in opinion which can be quite nuanced.

CONCLUSION
This pilot survey replicates well known research on clinician-industry
contact. Urologists are generally comfortable interacting with industry
representatives, and most feel that maintaining a relationship with
industry is important to both patient care and physician education.
Importantly, there persists an erroneous belief that contact with
industry representatives does not impact clinical decision-making.
Based on free-text feedback from the original survey, future iterations
will expand and clarify options for institutional limits on
contact/involvement with industry, and various opinion questions will
be rephrased to remove implicit bias.
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